[go: up one dir, main page]

AR108664A1 - VACCINE AGAINST INFECTIOUS BRONCHITIS - Google Patents

VACCINE AGAINST INFECTIOUS BRONCHITIS

Info

Publication number
AR108664A1
AR108664A1 ARP170101505A ARP170101505A AR108664A1 AR 108664 A1 AR108664 A1 AR 108664A1 AR P170101505 A ARP170101505 A AR P170101505A AR P170101505 A ARP170101505 A AR P170101505A AR 108664 A1 AR108664 A1 AR 108664A1
Authority
AR
Argentina
Prior art keywords
antigen
component
adjuvant
infectious bronchitis
ibd
Prior art date
Application number
ARP170101505A
Other languages
Spanish (es)
Inventor
Harmen Jacob Geerligs
Paul Joseph Dominowski
Dos Santos Maria Carolina Ferreira
De Freitas Carla Maria Batista
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of AR108664A1 publication Critical patent/AR108664A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Vacunas aviares contra la bronquitis infecciosa y la rinotraqueitis del pavo. Las vacunas tienen como adyuvante una emulsión de aceite que contiene un oligonucleótido inmunoestimulador. También métodos de uso de las vacunas. Reivindicación 1: Una composición inmunógena que comprende un componente antígeno y un componente adyuvante, caracterizada porque: a) el componente antígeno comprende al menos un antígeno de TRT y al menos un antígeno de IB, en donde al menos un antígeno de IB comprende un antígeno de IB QX; b) el componente adyuvante comprende un oligonucleótido inmunoestimulador y emulsión de aceite. Reivindicación 17: Una vacuna que comprende un componente antígeno y un componente adyuvante, caracterizada porque el componente adyuvante comprende un oligonucleótido inmunoestimulador y una emulsión de aceite, y en donde el componente antígeno comprende un antígeno de IBD. Reivindicación 18: La vacuna de acuerdo con la reivindicación 17, caracterizada porque dicho antígeno de IBD es un antígeno de cepa Lukert inactivado. Reivindicación 20: La vacuna de acuerdo con la reivindicación 18 ó 19, caracterizada porque el componente antígeno además comprende al menos uno de: a) un antígeno derivado de una cepa de IBD no Lukert; b) un antígeno de bronquitis infecciosa; c) un antígeno de reovirus; d) un antígeno de la enfermedad de Newcastle; e) un antígeno de rinotraqueitis del pavo.Avian vaccines against infectious bronchitis and turkey rhinotracheitis. Vaccines have as an adjuvant an oil emulsion containing an immunostimulatory oligonucleotide. Also methods of using vaccines. Claim 1: An immunogenic composition comprising an antigen component and an adjuvant component, characterized in that: a) the antigen component comprises at least one TRT antigen and at least one IB antigen, wherein at least one IB antigen comprises an antigen of IB QX; b) the adjuvant component comprises an immunostimulatory oligonucleotide and oil emulsion. Claim 17: A vaccine comprising an antigen component and an adjuvant component, characterized in that the adjuvant component comprises an immunostimulatory oligonucleotide and an oil emulsion, and wherein the antigen component comprises an IBD antigen. Claim 18: The vaccine according to claim 17, characterized in that said IBD antigen is an inactivated Lukert strain antigen. Claim 20: The vaccine according to claim 18 or 19, characterized in that the antigen component further comprises at least one of: a) an antigen derived from a non-Lukert strain of IBD; b) an infectious bronchitis antigen; c) a reovirus antigen; d) a Newcastle disease antigen; e) a turkey rhinotracheitis antigen.

ARP170101505A 2016-06-02 2017-06-01 VACCINE AGAINST INFECTIOUS BRONCHITIS AR108664A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662344598P 2016-06-02 2016-06-02

Publications (1)

Publication Number Publication Date
AR108664A1 true AR108664A1 (en) 2018-09-12

Family

ID=63667426

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101505A AR108664A1 (en) 2016-06-02 2017-06-01 VACCINE AGAINST INFECTIOUS BRONCHITIS

Country Status (1)

Country Link
AR (1) AR108664A1 (en)

Similar Documents

Publication Publication Date Title
MX2018014573A (en) VACCINE AGAINST ZIKA VIRUS.
AR133161A2 (en) Virus-like particle (VLP) vaccines against canine parvovirus (CPV) and their uses
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
CO2019011548A2 (en) Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogenic antigens
MX2020004543A (en) VACCINES AGAINST ZIKA, IMMUNOGENIC COMPOSITIONS AND METHODS USING THEM.
MX2019004593A (en) RECOMBINANT VECTORS THAT EXPRESS ANTIGENS OF AVIAN INFLUENZA VIRUSES AND USES OF THE SAME.
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
CO2017007057A2 (en) Foot and mouth disease vaccine
CO2018010874A2 (en) Live attenuated Zika virus vaccine
CL2018001946A1 (en) Attenuated viruses of infectious bronchitis.
WO2020012428A8 (en) New vaccines against avian reoviruses
AR097029A1 (en) ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE
CL2020002876A1 (en) Infectious Bronchitis Vaccine (Divisional Application No. 201803420)
BR112014023283A8 (en) IMMUNOGENIC COMPOSITION, SECOND IMMUNOGENIC COMPOSITION, AND METHOD FOR PREVENTION AND/OR TREATMENT AGAINST INFLUENZA DISEASE
AR108664A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS
AR115070A1 (en) STEM CELLS CONTAINING A SYNTHETIC CHIMERICAL VACCINE VIRUS AND METHODS FOR ITS USE
AR125960A2 (en) VACCINE FOR USE IN POULTRY AGAINST INFECTIOUS BURSITIS
UY32876A (en) IMMUNIZATION SCHEME FOR HETEROLOGICAL AWARENESS-REINFORCEMENT
EA202090236A1 (en) IMMUNOGENIC COMPOSITIONS OF SENECAVIRUS A AND WAYS WITH THEM
MX2018006500A (en) LIVE VIRUS THAT HAS A BANK OF DAMAGED VIRUSES OF VIRUSES, AND A VACCINE AGAINST DENGUE THAT CONTAINS HIMSELF AS ANTIGENS.
AR113832A1 (en) VACCINES AGAINST ZIKA, IMMUNOGENIC COMPOSITIONS AND METHODS USING THEM
NZ748375B2 (en) Vaccine against infectious bronchitis
BR112018013387A2 (en) recombinant vaccination vector, mva virus, vaccine or pharmaceutical composition and kit
EA201992167A1 (en) VACCINE
MX390292B (en) LIVE ATTENUATED HETEROLOGOUS VACCINE FOR LEPTOSPIA.

Legal Events

Date Code Title Description
FG Grant, registration